טוען...
Long‐term efficacy and safety results from an open‐label phase III study (UNCOVER‐J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab
BACKGROUND: Long‐term management of moderate‐to‐severe psoriasis is usually discussed in terms of continuous administration; however, there are many situations in clinical practice where treatment may be withdrawn with subsequent retreatment. OBJECTIVE: To assess the clinical course after ixekizumab...
שמור ב:
| הוצא לאור ב: | J Eur Acad Dermatol Venereol |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6587494/ https://ncbi.nlm.nih.gov/pubmed/30325534 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdv.15292 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|